Biomedical subjects

A Fratis

Publications and source records attributed to A Fratis.

3 recordsLinked to original sources

PubMed1990

Effect of food and antacid on absorption of orally administered ticlopidine hydrochloride.

Ticlopidine is a potent inhibitor of platelet aggregation. Absorption of ticlopidine after oral dosing is rapid and complete. Ticlopidine is extensively metabolized with a relative minor component of unchanged ticlopidine in plasma. The randomized crossover study described here was undertaken to examine the effect of food and antacid on the oral bioavailability of a single dose of ticlopidine (250 mg) in normal volunteers. After postprandial treatment the rate and extent of absorption of ticlopidine was earlier and greater relative to fasting treatment [tmax = 1.71 +/- 0.33 hr (fed) vs 1.92 +/- 0.56 hr (fasting) and AUC0-infinity = 2.164 +/- 0.813 micrograms X hr/mL (fed) vs 1.808 +/- 1.052 micrograms X hr/mL (fasting)]. The oral bioavailability of ticlopidine was increased by 20% when taken after a meal. In contrast, absorption of ticlopidine administered after antacid treatment was approximately 20% lower than under fasting conditions. Administration of ticlopidine with food is recommended to maximize gastrointestinal tolerance.

Administration, Oral↗

PubMed1989

Bioequivalence of two oral contraceptive drugs containing norethindrone and ethinyl estradiol.

Two oral contraceptive drugs, Formulation A and Formulation B, both of similar hormonal content, were compared with each other to determine if they were bioequivalent. Both drugs contain 1 mg of norethindrone (NET) and 0.035 mg of ethinyl estradiol (EE). Application of an interval test for the ratio of the computed parameter means demonstrated equivalence for the two formulations with respect to the 0-24 hour area under the plasma level versus time curve (AUC24), the total area under the curve (AUCtot) and for the maximum plasma concentration (Cmax) for both ethinyl estradiol and norethindrone. The data support the hypothesis for bioequivalence of the two formulations with respect to total absorption.

Adult↗

PubMed1978

Cloprednol bioavailability in humans.

The bioavailability of cloprednol, a new systemic corticosteroid, was examined in a 12-subject crossover study in which two capsules, a tablet, and a solution were tested. Plasma was analyzed for cloprednol by a GLC-mass spectrometric method. The biological half-life, peak plasma concentration, peak time, plasma concentration at all sampling times, and plasma areas were evaluated for differences (p less than or equal to 0.05) in comparisons of pairs among the four formulations. An analysis of variance revealed that cloprednol was absorbed to the same extent from all formulations and rapidly cleared from the plasma with a half-life of 1.86 +/- 0.36 (SD) hr. All plasma profile parameters from the solid dose formulations were the same, demonstrating bioequivalence in both rate and extent of absorption. Significant differences were observed between the solution and solid dose formulations with respect to peak time, 15-min plasma concentration, and 0-30 min area, indicative of faster absorption from the solution; however, total plasma areas were the same for all four formulations. Comparison of plasma cloprednol levels in this study to those of a prior intravenous-oral dose study suggests that cloprednol was completely bioavailable from all formulations.

Administration, Oral↗